

## Authorized Generic (AG) Frequently Asked Questions

### WHAT IS AN AG?

- An AG is a generic drug marketed under the same regulatory application (NDA) as the branded medication but differing in name and packaging
- An AG is therapeutically equivalent to the brand-name drug, identical in both active and inactive ingredients

### WHAT IS ASEGUA THERAPEUTICS?

- Asegua Therapeutics is the newly created subsidiary of Gilead Sciences that has launched an AG of EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg) and an AG of HARVONI® (ledipasvir 90 mg/sofosbuvir 400 mg)

### DOES THIS IMPACT MY RELATIONSHIP WITH MY GILEAD REPRESENTATIVE?

- This will not impact your relationship with your representative, who will continue to support you and your practice with relevant information from Gilead

### WHY IS ASEGUA THERAPEUTICS LAUNCHING AGs?

- Launching the AG of EPCLUSA and AG of HARVONI is the fastest way to offer a lower list price option without significant disruption to the healthcare system
- AGs serve as a bridge to longer-term solutions that aim to reduce patients' out-of-pocket costs and make these medications more accessible to patients

### WHAT IS THE COST OF THE AGs?


- The AGs have a list price of \$24,000 per course of therapy (the shortest durations of each treatment)
- The AGs are priced to more closely reflect the discounts that health insurers and government payers already receive

### HOW DOES PRESCRIBING WORK?

- You can continue to write “EPCLUSA” and “HARVONI” on the prescription for appropriate patients. In states where there are mandatory generic substitution laws and the AG is on formulary, prescriptions written for the branded product will be substituted with the AG
- In states with permissive substitution laws, pharmacies will substitute the AG based on instructions by payers
- You may also write “sofosbuvir 400 mg/velpatasvir 100 mg” or “ledipasvir 90 mg/sofosbuvir 400 mg”

## HOW ARE THE AGs SUPPLIED?

- Both AGs have the same type of packaging. The product is packaged in a blister pack. Each blister pack contains 28 tablets (2 blister cards, each containing 14 tablets)



## WILL THE AGs AFFECT MY PATIENTS' ACCESS TO TREATMENT?

- In the Medicare Part D setting, the AGs could lower out-of-pocket costs for some patients. The AGs could also open up access for many patients insured by Medicaid

## HOW CAN I GET MORE INFORMATION ABOUT COVERAGE?

- Support Path® and a co-pay coupon are available for eligible patients on an AG regimen. Support Path can help patients understand coverage and get started on treatment. Support Path offerings include Benefits Investigations, Prior Authorization and Appeals Information, Co-pay Coupon Program Enrollment, and Patient Assistance Program (PAP) Eligibility Screening
- For more information regarding Support Path, call 1-855-7-MYPATH (1-855-769-7284)

For more information regarding AGs, visit [www.asegua.com](http://www.asegua.com)

ASEGUA and the ASEGUA logo are trademarks of Asegua Therapeutics LLC. EPCLUSA, HARVONI, SUPPORT PATH and GILEAD are trademarks of Gilead Sciences, Inc., or one of its related companies and are used by permission. All other trademarks referenced herein are the property of their respective owners.

©2019 Gilead Sciences, Inc. All rights reserved. AGPP0014 04/19

Please see full Prescribing Information for [sofosbuvir/velpatasvir](#) and [ledipasvir/sofosbuvir](#), including **BOXED WARNING**.